This Title All WIREs
How to cite this WIREs title:
Impact Factor: 9.957

MicroRNAs as therapeutic targets in human cancers

Full article on Wiley Online Library:   HTML PDF

Can't access this content? Tell your librarian.

MicroRNAs (miRNAs) are evolutionarily conserved, small, regulatory RNAs that negatively regulate gene expression. Extensive research in the last decade has implicated miRNAs as master regulators of cellular processes with essential role in cancer initiation, progression, and metastasis, making them promising therapeutic tools for cancer management. In this article, we will briefly review the structure, biogenesis, functions, and mechanism of action of these miRNAs, followed by a detailed analysis of the therapeutic potential of these miRNAs. We will focus on the strategies presently used for miRNA therapy; discuss their use and drawbacks; and the challenges and future directions for the development of miRNA‐based therapy for human cancers. WIREs RNA 2014, 5:537–548. doi: 10.1002/wrna.1229 This article is categorized under: RNA in Disease and Development > RNA in Disease RNA in Disease and Development > RNA in Development

This WIREs title offers downloadable PowerPoint presentations of figures for non-profit, educational use, provided the content is not modified and full credit is given to the author and publication.

Download a PowerPoint presentation of all images

MicroRNA (miRNA) deregulation in human cancers. miRNA genes frequently undergo chromosomal deletions or translocations, epigenetic regulation, alterations in miRNA promoter activity by oncogenes and tumor suppressor genes, or alterations in the miRNA processing machinery resulting in widespread deregulation in their expression. Consequently, oncogenic miRNAs are upregulated, while tumor‐suppressive miRNAs are downregulated. This alteration at the miRNAome leads to aberrant changes in the transcriptome and proteome, causing cellular transformation and tumor progression.
[ Normal View | Magnified View ]
MicroRNA (miRNA) delivery options into the cells. Schematic representation of different delivery approaches currently investigated for the delivery of miRNA‐based therapeutics in cancer cells. Synthetic miRNAs can be delivered naked with different chemical modifications, conjugated with natural or synthetic polymers, conjugated with cholesterol molecules, complexed with liposomes, and encapsulated in nanoparticles using DNA–plasmid expression vectors or via viral expression vectors.
[ Normal View | Magnified View ]
MicroRNA (miRNA)‐based therapeutics for management of cancer. miRNA inhibition therapy for oncomiRs includes antisense anti‐miRs [anti‐miRNA oligonucleotides (AMOs), modified AMOs, locked nucleic acid (LNA)‐based AMOs, and antagomirs), small‐molecule inhibitors, miRNA sponges, and miRNA masks. miRNA replacement therapy for tumor‐suppressive miRs includes miRNA mimics, small‐molecule enhancers, and expression vectors. These approaches act at different stages of miRNA biogenesis, including processing, maturation, and strand selection.
[ Normal View | Magnified View ]

Related Articles

Cancer: An Interdisciplinary View

Browse by Topic

RNA in Disease and Development > RNA in Development
RNA in Disease and Development > RNA in Disease

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts